HF
CLRB icon

HRT Financial’s Cellectar Biosciences CLRB Stock Holding History

HRT Financial’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,578
Closed -$89K – 2942
2025
Q2 		$89K Buy
12,578
+11,037
+716% +$96.6K ﹤0.01% 2224
2025
Q1 		$14K Buy
+1,541
New +$14K ﹤0.01% 2328

Other funds holding CLRB

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
RCA
Riverview Capital Advisers Boston, Massachusetts $300M AUM 10.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HRT Financial's CLRB Position: Q3 2025 in Review

HRT Financial sold out of Cellectar Biosciences (CLRB) in Q3 2025, closing a stake of 12,578 shares — an estimated $89K sold.

HRT Financial first reported a position in CLRB in Q1 2025 and held it in 2 quarters. The position peaked at $89K in Q2 2025. 21 funds tracked by Wall St. Rank hold CLRB as of Q3 2025.

  • HRT Financial reported no remaining Cellectar Biosciences position as of Q3 2025 after selling out during the quarter.
  • HRT Financial sold 12,578 Cellectar Biosciences shares in Q3 2025, an estimated $89K.
  • HRT Financial first reported a position in Cellectar Biosciences in Q1 2025 and held it in 2 quarters.
  • HRT Financial's Cellectar Biosciences position peaked at $89K in Q2 2025.
  • 21 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2025.

Based on HRT Financial's 13F filing for Q3 2025, filed 14 Nov 2025.